Afyx Therapeutics A/S: Financial statements 2021
CVR: 38793594
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
Afyx Therapeutics A/S (CVR 38793594) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK 1,509,144 and a net result of DKK -814,180 compared with DKK -1,506,650 the year before. Equity in the 2021 report amounted to DKK 6,242,847. The solvency ratio was 63.9%. The company had 2 employees in the financial year.
- Gross Profit
- DKK 1,509,144
- Profit/Loss
- DKK -814,180
- Equity
- DKK 6,242,847
- Total Assets
- DKK 9,776,239
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | - | 1.5M | -814K | 6.2M | 2 |
| 2020 | - | -586K | -1.5M | 4.7M | 2 |
| 2019 | - | -1.1M | -1.6M | 1M | 1 |
Official annual report
Find more companies like Afyx Therapeutics A/S
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2021
As of October 7, 2021, Richard Henry Poulsen is registered as director of Afyx Therapeutics A/S.
As of October 7, 2021, Søren Anker Nielsen is registered as adm. dir. of Afyx Therapeutics A/S.
As of October 6, 2021, Richard Henry Poulsen has stepped down as adm. dir. of Afyx Therapeutics A/S.
Afyx Therapeutics A/S has published its annual report for 2020. Gross profit came to DKK -585,934, and the net result was DKK -1,506,650.
About Afyx Therapeutics A/S
Afyx Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2017. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Inphena A/S and Inphena ApS. The management consists of Claus Juan Møller-San Pedro. The board consists of Ole Baadsgaard (chair), Claus Juan Møller-San Pedro, Pia Leah Møller-San Pedro and Søren Mohrsen Kjær. The company is owned by Afyx Capital ApS. The company has 11 employees (2026). In 2025, the company reported a gross profit of DKK 23,138,320 and a net result of DKK 1,518,132 compared with DKK -3,810,585 the year before. Equity in the 2025 report amounted to DKK 36,178,254.
